Catalyst Pharma Merger Clears HSR Hurdle, Q3 Close Targeted
CPRX sits 65% above its 52-week low of $19.05.
Summary
Catalyst Pharmaceuticals' $4.1 billion acquisition by Angelini Pharma cleared a major regulatory hurdle with the FTC granting early termination of the HSR waiting period. This positive development follows the definitive merger agreement announced on May 7th. The deal, valued at $31.50 per share, is now expected to close in Q3 2026, subject to shareholder approval at the July 8th meeting.
At the time of this announcement, CPRX was trading at $31.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $19.05 to $32.56. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.